Post-earnings recap
Reported
Mon, Aug 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kiniksa Pharmaceuticals reported a loss of $0.68 per share for Q2 2019, with no revenue figures disclosed. The stock fell 3.34% following the report, reflecting investor concerns over the lack of guidance and clarity on future performance. The company is focusing on its clinical programs, but the absence of specific financial targets may lead to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.